Moderna expands convertible bond offering to up to $3 billion

Moderna has announced a significant financing move, expanding its planned issuance of senior convertible notes to a total potential volume of up to $3 billion. The offering includes an initial placement of $2.6 billion in non-interest-bearing notes due in 2032, with an additional $400 million option for initial purchasers. To mitigate potential shareholder dilution, the company has entered into capped-call transactions valued at approximately $285 million.

The biotechnology firm intends to use the net proceeds for general corporate purposes, specifically highlighting the expansion of its oncology business and the repayment of existing debt. This financial maneuver follows positive clinical developments, including successful Phase 3 trial results for a personalized mRNA melanoma vaccine developed in collaboration with Merck & Co.

While the stock has experienced volatility following the announcement due to dilution concerns, the company is leveraging its recent market momentum and clinical successes to secure long-term capital for its research and development pipeline.